Genmab A/S EBIT

As of the most recent data (September 2026), GNMSF shows a EBIT of $2.6B. That compares with $3.4B in the prior-year period — down 22.5% year over year. That is below the Healthcare sector average of $2T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GNMSF's EBIT is now $2.6B (was $3.4B) — a 22.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Genmab A/S is outperforming or lagging.

The Healthcare sector average EBIT is about $2T. Genmab A/S is at $2.6B, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how GNMSF stacks up against individual peers as well.

Tracking GNMSF's ebit over time shows whether Genmab A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $2.6B That compares with $3.4B in the prior-year period — down 22.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Genmab A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $2.6B) with ownership activity and broader fundamentals.